Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01026142
What this trial is testing

A Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 452
Large-scale testing (Phase 3)Not Yet RecruitingNCT07406542
What this trial is testing

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
Recurrent or Metastatic Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. 400
Testing effectiveness (Phase 2)Study completedNCT00146042
What this trial is testing

UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer

Who this might be right for
HER-2 Positive Metastatic Breast Cancer
University of Michigan Rogel Cancer Center 22
Early research (Phase 1)Study completedNCT02649686
What this trial is testing

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Who this might be right for
Metastatic Breast Cancer
Canadian Cancer Trials Group 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT05721248
What this trial is testing

STOP-HER2: Stopping Trastuzumab in HER2+ MBC

Who this might be right for
Breast CancerMetastatic Breast CancerHER2-positive Breast Cancer
Dana-Farber Cancer Institute 82
Early research (Phase 1)Active Not RecruitingNCT05508906
What this trial is testing

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Who this might be right for
Metastatic Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 190
Early research (Phase 1)Active Not RecruitingNCT04360941
What this trial is testing

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerLocally Advanced Breast CancerRecurrent Breast Cancer+3 more
Royal Marsden NHS Foundation Trust 45
Not applicableStudy completedNCT02913456
What this trial is testing

A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 629
Testing effectiveness (Phase 2)Active Not RecruitingNCT06445400
What this trial is testing

BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 83
Testing effectiveness (Phase 2)Looking for participantsNCT05095207
What this trial is testing

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Who this might be right for
Breast CancerMetastasis
Icahn School of Medicine at Mount Sinai 42
Testing effectiveness (Phase 2)Study completedNCT00006228
What this trial is testing

Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)UnknownNCT03913234
What this trial is testing

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

Who this might be right for
HER2-positive Breast CancerPostmenopausalMetastatic Breast Cancer
Yonsei University 95
Early research (Phase 1)Study completedNCT02780401
What this trial is testing

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

Who this might be right for
HER2/Neu NegativeNo Evidence of DiseaseOne or More Positive Axillary Nodes+8 more
University of Washington 32
Early research (Phase 1)Study completedNCT02025192
What this trial is testing

Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

Who this might be right for
HER2 Positive Metastatic Breast Cancers
Seagen Inc. 60
Large-scale testing (Phase 3)Study completedNCT00073528
What this trial is testing

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Novartis Pharmaceuticals 1,286
Early research (Phase 1)Ended earlyNCT05489679
What this trial is testing

AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 6
Testing effectiveness (Phase 2)Study completedNCT00736970
What this trial is testing

Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Who this might be right for
Breast CancerBreast Neoplasms
Merck Sharp & Dohme LLC 34
Testing effectiveness (Phase 2)Ended earlyNCT03289039
What this trial is testing

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 21
Testing effectiveness (Phase 2)Study completedNCT02129556
What this trial is testing

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer

Who this might be right for
Metastatic Breast Cancer
ETOP IBCSG Partners Foundation 58
Testing effectiveness (Phase 2)Active Not RecruitingNCT06428396
What this trial is testing

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Who this might be right for
Metastatic Breast Cancer
Merck Sharp & Dohme LLC 120
Next Page